Department of Anaesthesia and Intensive Care, CHU de Lille, Pôle d'Anesthésie Réanimation, Lille, France.
Department of Anaesthesia and Intensive Care, CHU de Lille, Pôle d'Anesthésie Réanimation, Lille, France.
World Neurosurg. 2021 Jun;150:e585-e590. doi: 10.1016/j.wneu.2021.03.068. Epub 2021 Mar 19.
Postoperative pain in spine surgery is an issue. Erector spinae plane block (ESPB) may reduce such postoperative pain, but its usefulness has never been evaluated in the specific context of trauma surgery. We thus studied the effect of bilateral ultrasound-guided ESPB on postoperative pain and opioid requirement after percutaneous lumbar arthrodesis for trauma.
All patients who underwent percutaneous lumbar arthrodesis for spine trauma between December 2019 and March 2020 were retrospectively studied. Some patients received preoperative bilateral ESPB (30 mL of 0.375% ropivacaine on each side; ESPB group), others received the standard of care (i.e., postoperative muscular infiltration with 30 mL of 0.75% of ropivacaine; control group), according to the preference of the anesthesiologist in charge of the patient. The rest of the management was identical in all patients. The primary outcome was the cumulative morphine consumption at 24 hours postoperatively. Secondary outcomes included pain score at various time points until 24 hours.
Fifty-five patients were included, of whom 24 received an EPSB and 31 received the standard of care. The cumulative morphine consumption (mean [standard deviation]) at 24 hours was 13 (12) mg in the ESPB group, and 35 (17) mg in the control group (P < 0.001). Pain scores were significantly lower in the ESPB group compared with the control group up to 9 hours after surgery (P < 0.01).
In this pilot study, compared with standard analgesia, ESPB reduced opioid requirement and postoperative pain after percutaneous lumbar arthrodesis for trauma. A randomized controlled trial is required to prove this effectiveness.
脊柱手术后的疼痛是一个问题。竖脊肌平面阻滞(ESPB)可能会减轻这种术后疼痛,但它在创伤外科的具体情况下的有效性从未得到过评估。因此,我们研究了双侧超声引导 ESPB 对创伤性经皮腰椎融合术后术后疼痛和阿片类药物需求的影响。
回顾性研究了 2019 年 12 月至 2020 年 3 月期间因脊柱创伤而行经皮腰椎融合术的所有患者。一些患者接受了术前双侧 ESPB(每侧 30 毫升 0.375%罗哌卡因;ESPB 组),另一些患者则接受了标准治疗(即术后肌肉浸润 30 毫升 0.75%罗哌卡因;对照组),这取决于负责患者的麻醉师的偏好。所有患者的其余治疗方法均相同。主要结局是术后 24 小时内累积吗啡消耗量。次要结局包括 24 小时内各时间点的疼痛评分。
共纳入 55 例患者,其中 24 例接受 ESPB,31 例接受标准治疗。ESPB 组术后 24 小时累积吗啡消耗量(平均值[标准差])为 13(12)mg,对照组为 35(17)mg(P <0.001)。与对照组相比,ESPB 组术后 9 小时内的疼痛评分显著降低(P <0.01)。
在这项初步研究中,与标准镇痛相比,ESPB 减少了创伤性经皮腰椎融合术后阿片类药物的需求和术后疼痛。需要进行随机对照试验来证明这种效果。